New XCOPRI was studied in adults with uncontrolled partial-onset seizures1
XCOPRI® (cenobamate tablets) CV was studied across 2 multicenter, randomized, double-blind, placebo-controlled studies in adult patients with partial-onset seizures with or without secondary generalization.1
concomitant antiepileptic drugs (AEDs) were not adequately controlling patients at baseline¹
were taking 2 or more
was the approximate
mean duration of
epilepsy for patients
in the studies¹
was the median
patients in both studies¹
In a study of adult patients with partial-onset seizures taking XCOPRI:
2X greater seizure reduction with XCOPRI vs placebo1
The primary outcome: Median percentage reduction in 28-day seizure frequency
*Statistically significant compared with placebo.
Discover the possibility of ZERO seizures with new XCOPRI1
Secondary outcome: Percentage of patients achieving seizure reductions of ≥75%, ≥90%, and 100%1,2
AS MANY AS 1 IN 5 PATIENTS EXPERIENCED ZERO SEIZURES1,4
Demonstrated to be effective in multiple types of partial-onset seizures
XCOPRI demonstrated reductions in seizure frequency across multiple types of partial-onset seizures compared with placebo2-4
Secondary outcome: Median percentage reduction in 28-day seizure frequency in partial-onset seizure subtypes2-4
†Partial-onset seizures=focal seizures; simple partial=focal aware seizure; complex partial=focal impaired; secondary generalized tonic-clonic=focal to bilateral tonic-clonic.5
‡Only patients with simple partial motor seizures were included in the study.
References: 1. XCOPRI [package insert]. Paramus, NJ: SK Life Science, Inc. 2. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1);38-48. 3. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(suppl):S1-S7. 4. Data on file. SK Life Science, Inc. 5. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League of Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(5):522-530.